#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Subcortical	_
1-2	12-17	local	_
1-3	18-28	functional	_
1-4	29-46	hyperconnectivity	_
1-5	47-49	in	_
1-6	50-58	cannabis	_
1-7	59-69	dependence	_
1-8	70-80	Background	_
1-9	81-89	Cannabis	_
1-10	90-95	abuse	_
1-11	96-99	has	_
1-12	100-104	been	_
1-13	105-115	associated	_
1-14	116-120	with	_
1-15	121-136	psychopathology	_
1-16	137-138	,	_
1-17	139-148	including	_
1-18	149-157	negative	_
1-19	158-170	emotionality	_
1-20	171-174	and	_
1-21	175-176	a	_
1-22	177-183	higher	_
1-23	184-188	risk	_
1-24	189-191	of	_
1-25	192-201	psychosis	_
1-26	202-203	,	_
1-27	204-216	particularly	_
1-28	217-221	with	_
1-29	222-227	early	_
1-30	228-231	age	_
1-31	232-234	of	_
1-32	235-245	initiation	_
1-33	246-247	.	_

2-1	248-255	However	_
2-2	256-257	,	_
2-3	258-261	the	_
2-4	262-272	mechanisms	_
2-5	273-283	underlying	_
2-6	284-288	this	_
2-7	289-300	association	_
2-8	301-304	are	_
2-9	305-311	poorly	_
2-10	312-322	understood	_
2-11	323-324	.	_

3-1	325-332	Because	_
3-2	333-341	aberrant	_
3-3	342-350	dopamine	_
3-4	351-352	(	_
3-5	353-355	DA	_
3-6	356-357	)	_
3-7	358-367	signaling	_
3-8	368-370	is	_
3-9	371-381	implicated	_
3-10	382-384	in	_
3-11	385-404	cannabis-associated	_
3-12	405-420	psychopathology	_
3-13	421-422	,	_
3-14	423-425	we	_
3-15	426-438	hypothesized	_
3-16	439-443	that	_
3-17	444-451	regular	_
3-18	452-460	cannabis	_
3-19	461-466	abuse	_
3-20	467-468	(	_
3-21	469-471	CA	_
3-22	472-473	)	_
3-23	474-479	would	_
3-24	480-482	be	_
3-25	483-493	associated	_
3-26	494-498	with	_
3-27	499-506	altered	_
3-28	507-514	resting	_
3-29	515-525	functional	_
3-30	526-538	connectivity	_
3-31	539-541	in	_
3-32	542-550	dopamine	_
3-33	551-568	midbrain-striatal	_
3-34	569-577	circuits	_
3-35	578-579	.	_

4-1	580-587	Methods	_
4-2	588-590	We	_
4-3	591-599	examined	_
4-4	600-607	resting	_
4-5	608-613	brain	_
4-6	614-622	activity	_
4-7	623-625	of	_
4-8	626-637	subcortical	_
4-9	638-645	regions	_
4-10	646-648	in	_
4-11	649-652	441	_
4-12	653-658	young	_
4-13	659-665	adults	_
4-14	666-670	from	_
4-15	671-674	the	_
4-16	675-680	Human	_
4-17	681-691	Connectome	_
4-18	692-699	Project	_
4-19	700-701	,	_
4-20	702-711	including	_
4-21	712-714	30	_
4-22	715-717	CA	_
4-23	718-725	meeting	_
4-24	726-729	DSM	_
4-25	730-738	criteria	_
4-26	739-742	for	_
4-27	743-753	dependence	_
4-28	754-755	,	_
4-29	756-759	and	_
4-30	760-762	30	_
4-31	763-771	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-32	772-779	matched	_
4-33	780-782	on	_
4-34	783-786	age	_
4-35	787-788	,	_
4-36	789-792	sex	_
4-37	793-794	,	_
4-38	795-804	education	_
4-39	805-806	,	_
4-40	807-810	BMI	_
4-41	811-812	,	_
4-42	813-820	anxiety	_
4-43	821-822	,	_
4-44	823-833	depression	_
4-45	834-835	,	_
4-46	836-839	and	_
4-47	840-855	alcohol/tobacco	_
4-48	856-861	usage	_
4-49	862-863	.	_

5-1	864-871	Results	_
5-2	872-878	Across	_
5-3	879-882	all	_
5-4	883-891	subjects	_
5-5	892-893	,	_
5-6	894-899	local	_
5-7	900-910	functional	_
5-8	911-923	connectivity	_
5-9	924-931	density	_
5-10	932-933	(	_
5-11	934-938	lFCD	_
5-12	939-940	)	_
5-13	941-945	hubs	_
5-14	946-948	in	_
5-15	949-960	subcortical	_
5-16	961-968	regions	_
5-17	969-973	were	_
5-18	974-978	most	_
5-19	979-988	prominent	_
5-20	989-991	in	_
5-21	992-999	ventral	_
5-22	1000-1008	striatum	_
5-23	1009-1010	,	_
5-24	1011-1022	hippocampus	_
5-25	1023-1024	,	_
5-26	1025-1033	amygdala	_
5-27	1034-1035	,	_
5-28	1036-1042	dorsal	_
5-29	1043-1051	midbrain	_
5-30	1052-1053	,	_
5-31	1054-1057	and	_
5-32	1058-1061	the	_
5-33	1062-1079	posterior-ventral	_
5-34	1080-1089	brainstem	_
5-35	1090-1091	.	_

6-1	1092-1094	As	_
6-2	1095-1107	hypothesized	_
6-3	1108-1109	,	_
6-4	1110-1112	CA	_
6-5	1113-1119	showed	_
6-6	1120-1128	markedly	_
6-7	1129-1138	increased	_
6-8	1139-1143	lFCD	_
6-9	1144-1152	relative	_
6-10	1153-1155	to	_
6-11	1156-1164	controls	_
6-12	1165-1167	in	_
6-13	1168-1175	ventral	_
6-14	1176-1184	striatum	_
6-15	1185-1186	(	_
6-16	1187-1192	where	_
6-17	1193-1200	nucleus	_
6-18	1201-1210	accumbens	_
6-19	1211-1213	is	_
6-20	1214-1221	located	_
6-21	1222-1223	)	_
6-22	1224-1227	and	_
6-23	1228-1236	midbrain	_
6-24	1237-1238	(	_
6-25	1239-1244	where	_
6-26	1245-1255	substantia	_
6-27	1256-1269	nigra/ventral	_
6-28	1270-1279	tegmental	_
6-29	1280-1286	nuclei	_
6-30	1287-1290	are	_
6-31	1291-1298	located	_
6-32	1299-1300	)	_
6-33	1301-1304	but	_
6-34	1305-1309	also	_
6-35	1310-1312	in	_
6-36	1313-1322	brainstem	_
6-37	1323-1326	and	_
6-38	1327-1334	lateral	_
6-39	1335-1343	thalamus	_
6-40	1344-1345	.	_

7-1	1346-1351	These	_
7-2	1352-1359	effects	_
7-3	1360-1364	were	_
7-4	1365-1373	observed	_
7-5	1374-1376	in	_
7-6	1377-1380	the	_
7-7	1381-1388	absence	_
7-8	1389-1391	of	_
7-9	1392-1403	significant	_
7-10	1404-1415	differences	_
7-11	1416-1418	in	_
7-12	1419-1430	subcortical	_
7-13	1431-1438	volumes	_
7-14	1439-1440	,	_
7-15	1441-1444	and	_
7-16	1445-1449	were	_
7-17	1450-1454	most	_
7-18	1455-1465	pronounced	_
7-19	1466-1468	in	_
7-20	1469-1472	the	_
7-21	1473-1484	individuals	_
7-22	1485-1488	who	_
7-23	1489-1494	began	_
7-24	1495-1503	cannabis	_
7-25	1504-1507	use	_
7-26	1508-1516	earliest	_
7-27	1517-1519	in	_
7-28	1520-1524	life	_
7-29	1525-1528	and	_
7-30	1529-1532	who	_
7-31	1533-1541	reported	_
7-32	1542-1546	high	_
7-33	1547-1553	levels	_
7-34	1554-1556	of	_
7-35	1557-1565	negative	_
7-36	1566-1578	emotionality	_
7-37	1579-1580	.	_

8-1	1581-1592	Conclusions	_
8-2	1593-1601	Together	_
8-3	1602-1603	,	_
8-4	1604-1609	these	_
8-5	1610-1618	findings	_
8-6	1619-1626	suggest	_
8-7	1627-1631	that	_
8-8	1632-1639	chronic	_
8-9	1640-1648	cannabis	_
8-10	1649-1654	abuse	_
8-11	1655-1657	is	_
8-12	1658-1668	associated	_
8-13	1669-1673	with	_
8-14	1674-1681	changes	_
8-15	1682-1684	in	_
8-16	1685-1692	resting	_
8-17	1693-1698	brain	_
8-18	1699-1707	function	_
8-19	1708-1709	,	_
8-20	1710-1722	particularly	_
8-21	1723-1725	in	_
8-22	1726-1738	dopaminergic	_
8-23	1739-1745	nuclei	_
8-24	1746-1756	implicated	_
8-25	1757-1759	in	_
8-26	1760-1769	psychosis	_
8-27	1770-1773	but	_
8-28	1774-1778	that	_
8-29	1779-1782	are	_
8-30	1783-1787	also	_
8-31	1788-1796	critical	_
8-32	1797-1800	for	_
8-33	1801-1806	habit	_
8-34	1807-1816	formation	_
8-35	1817-1820	and	_
8-36	1821-1827	reward	_
8-37	1828-1838	processing	_
8-38	1839-1840	.	_

9-1	1841-1846	These	_
9-2	1847-1854	results	_
9-3	1855-1859	shed	_
9-4	1860-1865	light	_
9-5	1866-1868	on	_
9-6	1869-1884	neurobiological	_
9-7	1885-1896	differences	_
9-8	1897-1901	that	_
9-9	1902-1905	may	_
9-10	1906-1908	be	_
9-11	1909-1917	relevant	_
9-12	1918-1920	to	_
9-13	1921-1936	psychopathology	_
9-14	1937-1947	associated	_
9-15	1948-1952	with	_
9-16	1953-1961	cannabis	_
9-17	1962-1965	use	_
9-18	1966-1967	.	_

10-1	1968-1977	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1978-1981	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1982-1989	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1990-2002	Participants	_
10-5	2003-2005	We	_
10-6	2006-2014	analyzed	_
10-7	2015-2019	data	_
10-8	2020-2024	from	_
10-9	2025-2028	the	_
10-10	2029-2033	S500	_
10-11	2034-2041	release	_
10-12	2042-2043	(	_
10-13	2044-2049	https	_
10-14	2050-2051	:	_
10-15	2052-2107	//www.humanconnectome.org/documentation/S500/index.html	_
10-16	2108-2109	)	_
10-17	2110-2112	of	_
10-18	2113-2116	the	_
10-19	2117-2124	WU-Minn	_
10-20	2125-2128	HCP	_
10-21	2129-2139	Consortium	_
10-22	2140-2141	.	_

11-1	2142-2144	We	_
11-2	2145-2149	only	_
11-3	2150-2158	included	_
11-4	2159-2171	participants	_
11-5	2172-2175	who	_
11-6	2176-2179	had	_
11-7	2180-2181	a	_
11-8	2182-2183	)	_
11-9	2184-2192	complete	_
11-10	2193-2203	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
11-11	2204-2207	and	_
11-12	2208-2214	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
11-13	2215-2222	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
11-14	2223-2227	data	_
11-15	2228-2232	that	_
11-16	2233-2239	passed	_
11-17	2240-2241	a	_
11-18	2242-2249	quality	_
11-19	2250-2259	assurance	_
11-20	2260-2265	check	_
11-21	2266-2267	,	_
11-22	2268-2271	and	_
11-23	2272-2273	b	_
11-24	2274-2275	)	_
11-25	2276-2284	complete	_
11-26	2285-2293	measures	_
11-27	2294-2296	of	_
11-28	2297-2306	cognitive	_
11-29	2307-2315	function	_
11-30	2316-2319	and	_
11-31	2320-2332	emotionality	_
11-32	2333-2334	(	_
11-33	2335-2340	total	_
11-34	2341-2346	n=441	_
11-35	2347-2359	participants	_
11-36	2360-2361	)	_
11-37	2362-2363	.	_

12-1	2364-2367	The	_
12-2	2368-2371	HCP	_
12-3	2372-2382	initiative	_
12-4	2383-2390	studied	_
12-5	2391-2396	young	_
12-6	2397-2403	adults	_
12-7	2404-2408	aged	_
12-8	2409-2414	22–35	_
12-9	2415-2419	from	_
12-10	2420-2421	a	_
12-11	2422-2426	wide	_
12-12	2427-2432	range	_
12-13	2433-2435	of	_
12-14	2436-2447	backgrounds	_
12-15	2448-2451	and	_
12-16	2452-2462	behavioral	_
12-17	2463-2471	profiles	_
12-18	2472-2486	representative	_
12-19	2487-2489	of	_
12-20	2490-2493	the	_
12-21	2494-2504	population	_
12-22	2505-2507	at	_
12-23	2508-2513	large	_
12-24	2514-2515	.	_

13-1	2516-2520	Thus	_
13-2	2521-2522	,	_
13-3	2523-2528	while	_
13-4	2529-2532	all	_
13-5	2533-2545	participants	_
13-6	2546-2549	are	_
13-7	2550-2560	considered	_
13-8	2561-2570	generally	_
13-9	2571-2578	healthy	_
13-10	2579-2580	,	_
13-11	2581-2593	participants	_
13-12	2594-2598	with	_
13-13	2599-2611	sub-clinical	_
13-14	2612-2623	psychiatric	_
13-15	2624-2638	symptomatology	_
13-16	2639-2642	and	_
13-17	2643-2655	recreational	_
13-18	2656-2660	drug	_
13-19	2661-2664	use	_
13-20	2665-2668	are	_
13-21	2669-2677	included	_
13-22	2678-2679	.	_

14-1	2680-2682	Of	_
14-2	2683-2686	the	_
14-3	2687-2690	441	_
14-4	2691-2703	participants	_
14-5	2704-2705	,	_
14-6	2706-2708	36	_
14-7	2709-2712	met	_
14-8	2713-2716	the	_
14-9	2717-2723	DSM-IV	_
14-10	2724-2732	criteria	_
14-11	2733-2736	for	_
14-12	2737-2745	cannabis	_
14-13	2746-2756	dependence	_
14-14	2757-2758	(	_
14-15	2759-2762	see	_
14-16	2763-2776	Supplementary	_
14-17	2777-2785	Material	_
14-18	2786-2789	for	_
14-19	2790-2791	a	_
14-20	2792-2803	description	_
14-21	2804-2805	)	_
14-22	2806-2807	.	_

15-1	2808-2813	Three	_
15-2	2814-2826	participants	_
15-3	2827-2831	were	_
15-4	2832-2840	excluded	_
15-5	2841-2844	for	_
15-6	2845-2853	comorbid	_
15-7	2854-2861	alcohol	_
15-8	2862-2872	dependence	_
15-9	2873-2876	and	_
15-10	2877-2880	one	_
15-11	2881-2884	was	_
15-12	2885-2893	excluded	_
15-13	2894-2897	for	_
15-14	2898-2905	anxiety	_
15-15	2906-2909	and	_
15-16	2910-2920	depression	_
15-17	2921-2928	ratings	_
15-18	2929-2930	>	_
15-19	2931-2932	3	_
15-20	2933-2935	SD	_
15-21	2936-2940	from	_
15-22	2941-2944	the	_
15-23	2945-2950	group	_
15-24	2951-2955	mean	_
15-25	2956-2957	.	_

16-1	2958-2964	Recent	_
16-2	2965-2972	studies	_
16-3	2973-2977	have	_
16-4	2978-2987	indicated	_
16-5	2988-2992	that	_
16-6	2993-2995	it	_
16-7	2996-2998	is	_
16-8	2999-3007	critical	_
16-9	3008-3010	in	_
16-10	3011-3018	studies	_
16-11	3019-3021	of	_
16-12	3022-3030	cannabis	_
16-13	3031-3036	abuse	_
16-14	3037-3039	to	_
16-15	3040-3046	select	_
16-16	3047-3048	a	_
16-17	3049-3061	well-matched	_
16-18	3062-3069	control	_
16-19	3070-3075	group	_
16-20	3076-3077	,	_
16-21	3078-3090	particularly	_
16-22	3091-3093	on	_
16-23	3094-3102	measures	_
16-24	3103-3105	of	_
16-25	3106-3113	alcohol	_
16-26	3114-3117	and	_
16-27	3118-3125	tobacco	_
16-28	3126-3131	usage	_
16-29	3132-3133	,	_
16-30	3134-3138	e.g.	_
16-31	3139-3140	,	_
16-32	3141-3142	.	_

17-1	3143-3152	Therefore	_
17-2	3153-3154	,	_
17-3	3155-3157	we	_
17-4	3158-3165	matched	_
17-5	3166-3172	groups	_
17-6	3173-3175	on	_
17-7	3176-3179	age	_
17-8	3180-3181	,	_
17-9	3182-3185	sex	_
17-10	3186-3187	,	_
17-11	3188-3197	education	_
17-12	3198-3199	,	_
17-13	3200-3203	BMI	_
17-14	3204-3205	,	_
17-15	3206-3213	anxiety	_
17-16	3214-3215	,	_
17-17	3216-3226	depression	_
17-18	3227-3228	,	_
17-19	3229-3232	and	_
17-20	3233-3240	alcohol	_
17-21	3241-3244	and	_
17-22	3245-3252	tobacco	_
17-23	3253-3258	usage	_
17-24	3259-3260	(	_
17-25	3261-3263	we	_
17-26	3264-3274	calculated	_
17-27	3275-3284	composite	_
17-28	3285-3300	tobacco/alcohol	_
17-29	3301-3306	usage	_
17-30	3307-3310	the	_
17-31	3311-3315	same	_
17-32	3316-3319	way	_
17-33	3320-3322	as	_
17-34	3323-3324	a	_
17-35	3325-3331	recent	_
17-36	3332-3337	study	_
17-37	3338-3340	of	_
17-38	3341-3344	HCP	_
17-39	3345-3349	data	_
17-40	3350-3351	;	_
17-41	3352-3355	see	_
17-42	3356-3369	Supplementary	_
17-43	3370-3378	Material	_
17-44	3379-3382	and	_
17-45	3383-3384	)	_
17-46	3385-3386	.	_

18-1	3387-3390	Two	_
18-2	3391-3399	subjects	_
18-3	3400-3404	from	_
18-4	3405-3409	each	_
18-5	3410-3415	group	_
18-6	3416-3420	were	_
18-7	3421-3429	excluded	_
18-8	3430-3432	to	_
18-9	3433-3439	ensure	_
18-10	3440-3446	groups	_
18-11	3447-3451	were	_
18-12	3452-3459	matched	_
18-13	3460-3462	on	_
18-14	3463-3470	tobacco	_
18-15	3471-3476	usage	_
18-16	3477-3478	(	_
18-17	3479-3492	Supplementary	_
18-18	3493-3501	Material	_
18-19	3502-3503	)	_
18-20	3504-3505	,	_
18-21	3506-3515	therefore	_
18-22	3516-3519	the	_
18-23	3520-3525	final	_
18-24	3526-3532	sample	_
18-25	3533-3541	included	_
18-26	3542-3544	30	_
18-27	3545-3547	CA	_
18-28	3548-3551	and	_
18-29	3552-3554	30	_
18-30	3555-3563	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-31	3564-3565	;	_
18-32	3566-3578	demographics	_
18-33	3579-3582	and	_
18-34	3583-3594	statistical	_
18-35	3595-3600	tests	_
18-36	3601-3604	are	_
18-37	3605-3614	presented	_
18-38	3615-3617	in	_
18-39	3618-3623	Table	_
18-40	3624-3625	1	_
18-41	3626-3627	.	_

19-1	3628-3638	Behavioral	_
19-2	3639-3647	Measures	_
19-3	3648-3650	of	_
19-4	3651-3659	Interest	_
19-5	3660-3662	We	_
19-6	3663-3671	examined	_
19-7	3672-3676	data	_
19-8	3677-3684	related	_
19-9	3685-3687	to	_
19-10	3688-3697	cognitive	_
19-11	3698-3706	function	_
19-12	3707-3710	and	_
19-13	3711-3719	negative	_
19-14	3720-3732	emotionality	_
19-15	3733-3734	,	_
19-16	3735-3740	given	_
19-17	3741-3744	the	_
19-18	3745-3753	interest	_
19-19	3754-3756	in	_
19-20	3757-3766	potential	_
19-21	3767-3774	chronic	_
19-22	3775-3782	effects	_
19-23	3783-3785	of	_
19-24	3786-3794	cannabis	_
19-25	3795-3797	in	_
19-26	3798-3803	these	_
19-27	3804-3811	domains	_
19-28	3812-3813	.	_

20-1	3814-3826	Participants	_
20-2	3827-3836	completed	_
20-3	3837-3844	various	_
20-4	3845-3848	NIH	_
20-5	3849-3856	toolbox	_
20-6	3857-3865	measures	_
20-7	3866-3868	as	_
20-8	3869-3873	part	_
20-9	3874-3876	of	_
20-10	3877-3880	the	_
20-11	3881-3884	HCP	_
20-12	3885-3886	.	_

21-1	3887-3889	We	_
21-2	3890-3894	were	_
21-3	3895-3907	particularly	_
21-4	3908-3918	interested	_
21-5	3919-3921	in	_
21-6	3922-3930	relating	_
21-7	3931-3934	the	_
21-8	3935-3942	current	_
21-9	3943-3947	work	_
21-10	3948-3950	to	_
21-11	3951-3954	our	_
21-12	3955-3963	previous	_
21-13	3964-3972	findings	_
21-14	3973-3977	that	_
21-15	3978-3980	CA	_
21-16	3981-3984	are	_
21-17	3985-3995	vulnerable	_
21-18	3996-3998	to	_
21-19	3999-4007	feelings	_
21-20	4008-4010	of	_
21-21	4011-4021	alienation	_
21-22	4022-4023	,	_
21-23	4024-4027	i.e	_
21-24	4028-4029	.	_

22-1	4030-4033	the	_
22-2	4034-4040	belief	_
22-3	4041-4045	that	_
22-4	4046-4052	others	_
22-5	4053-4057	wish	_
22-6	4058-4062	them	_
22-7	4063-4067	harm	_
22-8	4068-4069	,	_
22-9	4070-4073	and	_
22-10	4074-4078	that	_
22-11	4079-4083	they	_
22-12	4084-4087	are	_
22-13	4088-4096	betrayed	_
22-14	4097-4099	or	_
22-15	4100-4108	deceived	_
22-16	4109-4111	by	_
22-17	4112-4119	friends	_
22-18	4120-4121	.	_

23-1	4122-4129	However	_
23-2	4130-4131	,	_
23-3	4132-4135	our	_
23-4	4136-4144	previous	_
23-5	4145-4149	work	_
23-6	4150-4154	used	_
23-7	4155-4158	the	_
23-8	4159-4175	Multidimensional	_
23-9	4176-4187	Personality	_
23-10	4188-4201	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-11	4202-4203	(	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-12	4204-4207	MPQ	_
23-13	4208-4209	)	_
23-14	4210-4213	and	_
23-15	4214-4218	this	_
23-16	4219-4222	was	_
23-17	4223-4226	not	_
23-18	4227-4239	administered	_
23-19	4240-4242	as	_
23-20	4243-4247	part	_
23-21	4248-4250	of	_
23-22	4251-4254	the	_
23-23	4255-4258	HCP	_
23-24	4259-4267	protocol	_
23-25	4268-4269	.	_

24-1	4270-4279	Therefore	_
24-2	4280-4281	,	_
24-3	4282-4284	we	_
24-4	4285-4294	attempted	_
24-5	4295-4297	to	_
24-6	4298-4302	find	_
24-7	4303-4312	analogous	_
24-8	4313-4321	measures	_
24-9	4322-4325	for	_
24-10	4326-4329	the	_
24-11	4330-4335	three	_
24-12	4336-4340	main	_
24-13	4341-4348	domains	_
24-14	4349-4351	of	_
24-15	4352-4355	the	_
24-16	4356-4359	MPQ	_
24-17	4360-4361	:	_
24-18	4362-4368	stress	_
24-19	4369-4379	reactivity	_
24-20	4380-4381	,	_
24-21	4382-4392	aggression	_
24-22	4393-4394	,	_
24-23	4395-4398	and	_
24-24	4399-4409	alienation	_
24-25	4410-4411	.	_

25-1	4412-4415	For	_
25-2	4416-4422	stress	_
25-3	4423-4433	reactivity	_
25-4	4434-4435	,	_
25-5	4436-4438	we	_
25-6	4439-4443	used	_
25-7	4444-4447	the	_
25-8	4448-4449	“	_
25-9	4450-4459	perceived	_
25-10	4460-4466	stress	_
25-11	4467-4468	”	_
25-12	4469-4476	measure	_
25-13	4477-4478	;	_
25-14	4479-4482	for	_
25-15	4483-4493	aggression	_
25-16	4494-4495	,	_
25-17	4496-4498	we	_
25-18	4499-4507	averaged	_
25-19	4508-4516	together	_
25-20	4517-4520	the	_
25-21	4521-4529	Z-scores	_
25-22	4530-4532	of	_
25-23	4533-4534	“	_
25-24	4535-4540	Anger	_
25-25	4541-4550	Hostility	_
25-26	4551-4552	”	_
25-27	4553-4556	and	_
25-28	4557-4558	“	_
25-29	4559-4564	Anger	_
25-30	4565-4575	Aggression	_
25-31	4576-4577	”	_
25-32	4578-4579	(	_
25-33	4580-4584	i.e.	_
25-34	4585-4586	,	_
25-35	4587-4590	one	_
25-36	4591-4592	’	_
25-37	4593-4594	s	_
25-38	4595-4598	own	_
25-39	4599-4607	behavior	_
25-40	4608-4610	in	_
25-41	4611-4614	the	_
25-42	4615-4620	anger	_
25-43	4621-4624	and	_
25-44	4625-4635	aggressive	_
25-45	4636-4643	domains	_
25-46	4644-4645	)	_
25-47	4646-4647	;	_
25-48	4648-4651	and	_
25-49	4652-4655	for	_
25-50	4656-4666	alienation	_
25-51	4667-4669	we	_
25-52	4670-4678	averaged	_
25-53	4679-4687	together	_
25-54	4688-4691	the	_
25-55	4692-4700	Z-scores	_
25-56	4701-4703	of	_
25-57	4704-4705	“	_
25-58	4706-4715	Perceived	_
25-59	4716-4725	Hostility	_
25-60	4726-4727	”	_
25-61	4728-4731	and	_
25-62	4732-4733	“	_
25-63	4734-4743	Perceived	_
25-64	4744-4753	Rejection	_
25-65	4754-4755	”	_
25-66	4756-4757	(	_
25-67	4758-4762	i.e.	_
25-68	4763-4764	,	_
25-69	4765-4768	how	_
25-70	4769-4772	one	_
25-71	4773-4782	perceives	_
25-72	4783-4789	others	_
25-73	4790-4798	behaving	_
25-74	4799-4806	towards	_
25-75	4807-4811	them	_
25-76	4812-4813	)	_
25-77	4814-4815	.	_

26-1	4816-4818	We	_
26-2	4819-4823	then	_
26-3	4824-4832	averaged	_
26-4	4833-4841	together	_
26-5	4842-4847	these	_
26-6	4848-4854	stress	_
26-7	4855-4856	,	_
26-8	4857-4867	aggression	_
26-9	4868-4869	,	_
26-10	4870-4873	and	_
26-11	4874-4884	alienation	_
26-12	4885-4893	measures	_
26-13	4894-4902	together	_
26-14	4903-4906	for	_
26-15	4907-4908	a	_
26-16	4909-4918	composite	_
26-17	4919-4927	negative	_
26-18	4928-4940	emotionality	_
26-19	4941-4946	score	_
26-20	4947-4948	.	_

27-1	4949-4952	All	_
27-2	4953-4958	three	_
27-3	4959-4966	domains	_
27-4	4967-4971	were	_
27-5	4972-4980	included	_
27-6	4981-4983	to	_
27-7	4984-4991	examine	_
27-8	4992-4994	if	_
27-9	4995-4998	the	_
27-10	4999-5006	effects	_
27-11	5007-5011	were	_
27-12	5012-5020	specific	_
27-13	5021-5023	to	_
27-14	5024-5034	alienation	_
27-15	5035-5036	.	_

28-1	5037-5041	More	_
28-2	5042-5055	comprehensive	_
28-3	5056-5068	descriptions	_
28-4	5069-5071	of	_
28-5	5072-5081	cognitive	_
28-6	5082-5085	and	_
28-7	5086-5095	emotional	_
28-8	5096-5104	measures	_
28-9	5105-5108	are	_
28-10	5109-5118	available	_
28-11	5119-5121	in	_
28-12	5122-5135	Supplementary	_
28-13	5136-5144	Material	_
28-14	5145-5148	and	_
28-15	5149-5154	https	_
28-16	5155-5156	:	_
28-17	5157-5249	//wiki.humanconnectome.org/display/PublicData/HCP+Data+Dictionary+Public+500+Subject+Release	_
28-18	5250-5251	.	_

29-1	5252-5255	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-2	5256-5261	image	_
29-3	5262-5273	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Education
29-4	5274-5277	and	_
29-5	5278-5291	preprocessing	_
29-6	5292-5295	All	_
29-7	5296-5301	brain	_
29-8	5302-5308	images	_
29-9	5309-5313	were	_
29-10	5314-5323	collected	_
29-11	5324-5326	on	_
29-12	5327-5328	a	_
29-13	5329-5336	Siemens	_
29-14	5337-5339	3T	_
29-15	5340-5341	“	_
29-16	5342-5352	connectome	_
29-17	5353-5358	Skyra	_
29-18	5359-5360	”	_
29-19	5361-5368	scanner	_
29-20	5369-5373	with	_
29-21	5374-5375	a	_
29-22	5376-5386	32-channel	_
29-23	5387-5391	coil	_
29-24	5392-5394	at	_
29-25	5395-5405	Washington	_
29-26	5406-5416	University	_
29-27	5417-5419	in	_
29-28	5420-5423	St.	_
29-29	5424-5429	Louis	_
29-30	5430-5431	.	_

30-1	5432-5435	T1-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-2	5436-5439	and	_
30-3	5440-5451	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
30-4	5452-5462	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
30-5	5463-5468	scans	_
30-6	5469-5473	were	_
30-7	5474-5482	acquired	_
30-8	5483-5484	(	_
30-9	5485-5492	FOV=224	_
30-10	5493-5495	mm	_
30-11	5496-5497	,	_
30-12	5498-5508	matrix=320	_
30-13	5509-5510	,	_
30-14	5511-5514	256	_
30-15	5515-5521	slices	_
30-16	5522-5523	,	_
30-17	5524-5527	0.7	_
30-18	5528-5530	mm	_
30-19	5531-5540	isotropic	_
30-20	5541-5547	voxels	_
30-21	5548-5549	)	_
30-22	5550-5551	.	_

31-1	5552-5558	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-2	5559-5564	scans	_
31-3	5565-5569	were	_
31-4	5570-5578	acquired	_
31-5	5579-5583	with	_
31-6	5584-5586	an	_
31-7	5587-5590	EPI	_
31-8	5591-5599	sequence	_
31-9	5600-5601	(	_
31-10	5602-5611	Multiband	_
31-11	5612-5618	factor	_
31-12	5619-5620	=	_
31-13	5621-5622	8	_
31-14	5623-5624	,	_
31-15	5625-5627	TR	_
31-16	5628-5629	=	_
31-17	5630-5633	720	_
31-18	5634-5636	ms	_
31-19	5637-5638	,	_
31-20	5639-5641	TE	_
31-21	5642-5643	=	_
31-22	5644-5648	33.1	_
31-23	5649-5651	ms	_
31-24	5652-5653	,	_
31-25	5654-5658	flip	_
31-26	5659-5664	angle	_
31-27	5665-5666	=	_
31-28	5667-5670	52°	_
31-29	5671-5672	,	_
31-30	5673-5676	FOV	_
31-31	5677-5678	=	_
31-32	5679-5682	208	_
31-33	5683-5685	mm	_
31-34	5686-5687	,	_
31-35	5688-5691	104	_
31-36	5692-5693	×	_
31-37	5694-5696	90	_
31-38	5697-5703	matrix	_
31-39	5704-5705	,	_
31-40	5706-5708	72	_
31-41	5709-5715	slices	_
31-42	5716-5718	of	_
31-43	5719-5720	2	_
31-44	5721-5723	mm	_
31-45	5724-5733	isotropic	_
31-46	5734-5740	voxels	_
31-47	5741-5742	,	_
31-48	5743-5745	no	_
31-49	5746-5749	gap	_
31-50	5750-5751	)	_
31-51	5752-5753	.	_

32-1	5754-5757	Two	_
32-2	5758-5766	sessions	_
32-3	5767-5771	were	_
32-4	5772-5781	completed	_
32-5	5782-5786	with	_
32-6	5787-5790	two	_
32-7	5791-5797	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
32-8	5798-5803	scans	_
32-9	5804-5805	(	_
32-10	5806-5809	one	_
32-11	5810-5812	LR	_
32-12	5813-5816	and	_
32-13	5817-5820	one	_
32-14	5821-5823	RL	_
32-15	5824-5829	phase	_
32-16	5830-5838	encoding	_
32-17	5839-5840	)	_
32-18	5841-5843	in	_
32-19	5844-5848	each	_
32-20	5849-5856	session	_
32-21	5857-5858	.	_

33-1	5859-5863	Each	_
33-2	5864-5868	scan	_
33-3	5869-5872	was	_
33-4	5873-5878	14:33	_
33-5	5879-5882	min	_
33-6	5883-5884	,	_
33-7	5885-5888	for	_
33-8	5889-5890	a	_
33-9	5891-5896	total	_
33-10	5897-5899	of	_
33-11	5900-5905	54:15	_
33-12	5906-5909	min	_
33-13	5910-5911	.	_

34-1	5912-5915	For	_
34-2	5916-5922	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
34-3	5923-5924	,	_
34-4	5925-5937	participants	_
34-5	5938-5942	were	_
34-6	5943-5953	instructed	_
34-7	5954-5956	to	_
34-8	5957-5960	lie	_
34-9	5961-5965	with	_
34-10	5966-5970	eyes	_
34-11	5971-5975	open	_
34-12	5976-5977	,	_
34-13	5978-5980	to	_
34-14	5981-5986	relax	_
34-15	5987-5990	and	_
34-16	5991-5995	look	_
34-17	5996-5998	at	_
34-18	5999-6000	a	_
34-19	6001-6006	white	_
34-20	6007-6012	cross	_
34-21	6013-6015	on	_
34-22	6016-6017	a	_
34-23	6018-6022	dark	_
34-24	6023-6033	background	_
34-25	6034-6035	,	_
34-26	6036-6041	think	_
34-27	6042-6044	of	_
34-28	6045-6052	nothing	_
34-29	6053-6056	and	_
34-30	6057-6059	to	_
34-31	6060-6063	not	_
34-32	6064-6068	fall	_
34-33	6069-6075	asleep	_
34-34	6076-6077	.	_

35-1	6078-6081	For	_
35-2	6082-6089	further	_
35-3	6090-6097	details	_
35-4	6098-6100	on	_
35-5	6101-6106	image	_
35-6	6107-6118	acquisition	_
35-7	6119-6120	,	_
35-8	6121-6124	see	_
35-9	6125-6130	https	_
35-10	6131-6132	:	_
35-11	6133-6214	//www.humanconnectome.org/documentation/S500/HCP_S500+MEG2_Release_Appendix_I.pdf	_
35-12	6215-6216	.	_

36-1	6217-6220	For	_
36-2	6221-6229	analysis	_
36-3	6230-6232	of	_
36-4	6233-6239	rsfMRI	_
36-5	6240-6244	data	_
36-6	6245-6246	,	_
36-7	6247-6249	we	_
36-8	6250-6254	used	_
36-9	6255-6258	the	_
36-10	6259-6260	“	_
36-11	6261-6268	minimal	_
36-12	6269-6282	preprocessing	_
36-13	6283-6284	”	_
36-14	6285-6293	datasets	_
36-15	6294-6295	(	_
36-16	6296-6312	hp2000_clean.nii	_
36-17	6313-6318	files	_
36-18	6319-6320	)	_
36-19	6321-6322	,	_
36-20	6323-6328	where	_
36-21	6329-6342	preprocessing	_
36-22	6343-6351	included	_
36-23	6352-6353	:	_
36-24	6354-6355	a	_
36-25	6356-6357	)	_
36-26	6358-6366	gradient	_
36-27	6367-6377	distortion	_
36-28	6378-6388	correction	_
36-29	6389-6390	,	_
36-30	6391-6392	b	_
36-31	6393-6394	)	_
36-32	6395-6400	rigid	_
36-33	6401-6405	body	_
36-34	6406-6417	realignment	_
36-35	6418-6419	,	_
36-36	6420-6421	c	_
36-37	6422-6423	)	_
36-38	6424-6429	field	_
36-39	6430-6433	map	_
36-40	6434-6444	processing	_
36-41	6445-6446	,	_
36-42	6447-6448	d	_
36-43	6449-6450	)	_
36-44	6451-6460	nonlinear	_
36-45	6461-6474	normalization	_
36-46	6475-6477	to	_
36-47	6478-6481	MNI	_
36-48	6482-6487	space	_
36-49	6488-6489	,	_
36-50	6490-6491	e	_
36-51	6492-6493	)	_
36-52	6494-6503	high-pass	_
36-53	6504-6513	filtering	_
36-54	6514-6518	with	_
36-55	6519-6530	independent	_
36-56	6531-6540	component	_
36-57	6541-6549	analysis	_
36-58	6550-6551	(	_
36-59	6552-6555	ICA	_
36-60	6556-6557	)	_
36-61	6558-6564	-based	_
36-62	6565-6574	denoising	_
36-63	6575-6576	,	_
36-64	6577-6580	and	_
36-65	6581-6582	f	_
36-66	6583-6584	)	_
36-67	6585-6590	brain	_
36-68	6591-6598	masking	_
36-69	6599-6600	.	_

37-1	6601-6603	In	_
37-2	6604-6607	our	_
37-3	6608-6611	own	_
37-4	6612-6622	subsequent	_
37-5	6623-6636	preprocessing	_
37-6	6637-6638	,	_
37-7	6639-6641	we	_
37-8	6642-6649	removed	_
37-9	6650-6660	timepoints	_
37-10	6661-6665	that	_
37-11	6666-6670	were	_
37-12	6671-6679	severely	_
37-13	6680-6688	affected	_
37-14	6689-6691	by	_
37-15	6692-6698	motion	_
37-16	6699-6704	using	_
37-17	6705-6706	a	_
37-18	6707-6708	‘	_
37-19	6709-6718	scrubbing	_
37-20	6719-6720	’	_
37-21	6721-6729	approach	_
37-22	6730-6731	(	_
37-23	6732-6745	Supplementary	_
37-24	6746-6754	Material	_
37-25	6755-6756	)	_
37-26	6757-6758	.	_

38-1	6759-6768	Remaining	_
38-2	6769-6775	motion	_
38-3	6776-6783	effects	_
38-4	6784-6786	on	_
38-5	6787-6791	fMRI	_
38-6	6792-6796	time	_
38-7	6797-6803	series	_
38-8	6804-6808	were	_
38-9	6809-6818	regressed	_
38-10	6819-6822	out	_
38-11	6823-6828	using	_
38-12	6829-6832	the	_
38-13	6833-6836	six	_
38-14	6837-6848	translation	_
38-15	6849-6852	and	_
38-16	6853-6861	rotation	_
38-17	6862-6872	regressors	_
38-18	6873-6874	.	_

39-1	6875-6882	Finally	_
39-2	6883-6884	,	_
39-3	6885-6894	band-pass	_
39-4	6895-6903	temporal	_
39-5	6904-6913	filtering	_
39-6	6914-6915	(	_
39-7	6916-6925	0.01–0.10	_
39-8	6926-6928	Hz	_
39-9	6929-6930	)	_
39-10	6931-6934	was	_
39-11	6935-6942	applied	_
39-12	6943-6944	.	_

40-1	6945-6949	lFCD	_
40-2	6950-6953	was	_
40-3	6954-6962	computed	_
40-4	6963-6973	separately	_
40-5	6974-6976	on	_
40-6	6977-6981	each	_
40-7	6982-6984	of	_
40-8	6985-6988	the	_
40-9	6989-6993	four	_
40-10	6994-6998	runs	_
40-11	6999-7001	of	_
40-12	7002-7011	processed	_
40-13	7012-7013	,	_
40-14	7014-7024	unsmoothed	_
40-15	7025-7029	data	_
40-16	7030-7031	,	_
40-17	7032-7038	masked	_
40-18	7039-7041	by	_
40-19	7042-7046	each	_
40-20	7047-7058	participant	_
40-21	7059-7060	’	_
40-22	7061-7062	s	_
40-23	7063-7073	FreeSurfer	_
40-24	7074-7085	subcortical	_
40-25	7086-7098	parcellation	_
40-26	7099-7100	(	_
40-27	7101-7116	wmparc.2.nii.gz	_
40-28	7117-7118	)	_
40-29	7119-7120	,	_
40-30	7121-7126	which	_
40-31	7127-7135	included	_
40-32	7136-7145	bilateral	_
40-33	7146-7154	thalamus	_
40-34	7155-7156	,	_
40-35	7157-7164	caudate	_
40-36	7165-7166	,	_
40-37	7167-7174	putamen	_
40-38	7175-7176	,	_
40-39	7177-7185	pallidum	_
40-40	7186-7187	,	_
40-41	7188-7196	amygdala	_
40-42	7197-7198	,	_
40-43	7199-7206	nucleus	_
40-44	7207-7216	accumbens	_
40-45	7217-7218	,	_
40-46	7219-7230	hippocampus	_
40-47	7231-7232	,	_
40-48	7233-7241	midbrain	_
40-49	7242-7245	and	_
40-50	7246-7255	brainstem	_
40-51	7256-7257	(	_
40-52	7258-7261	see	_
40-53	7262-7267	Local	_
40-54	7268-7271	FCD	_
40-55	7272-7279	section	_
40-56	7280-7285	below	_
40-57	7286-7287	)	_
40-58	7288-7289	.	_

41-1	7290-7297	Finally	_
41-2	7298-7299	,	_
41-3	7300-7303	the	_
41-4	7304-7308	four	_
41-5	7309-7318	resulting	_
41-6	7319-7323	lFCD	_
41-7	7324-7328	maps	_
41-8	7329-7330	(	_
41-9	7331-7336	LR/RL	_
41-10	7337-7338	;	_
41-11	7339-7350	REST1/REST2	_
41-12	7351-7352	)	_
41-13	7353-7357	were	_
41-14	7358-7366	averaged	_
41-15	7367-7375	together	_
41-16	7376-7379	and	_
41-17	7380-7388	averaged	_
41-18	7389-7395	images	_
41-19	7396-7400	were	_
41-20	7401-7409	smoothed	_
41-21	7410-7412	at	_
41-22	7413-7416	2mm	_
41-23	7417-7421	FWHM	_
41-24	7422-7423	.	_

42-1	7424-7429	Local	_
42-2	7430-7433	FCD	_
42-3	7434-7435	(	_
42-4	7436-7440	lFCD	_
42-5	7441-7442	)	_
42-6	7443-7451	analysis	_
42-7	7452-7455	The	_
42-8	7456-7463	Pearson	_
42-9	7464-7475	correlation	_
42-10	7476-7479	was	_
42-11	7480-7484	used	_
42-12	7485-7487	to	_
42-13	7488-7494	assess	_
42-14	7495-7498	the	_
42-15	7499-7507	strength	_
42-16	7508-7510	of	_
42-17	7511-7521	functional	_
42-18	7522-7534	connectivity	_
42-19	7535-7536	,	_
42-20	7537-7540	Cij	_
42-21	7541-7542	,	_
42-22	7543-7550	between	_
42-23	7551-7557	voxels	_
42-24	7558-7559	i	_
42-25	7560-7563	and	_
42-26	7564-7565	j	_
42-27	7566-7567	.	_

43-1	7568-7569	A	_
43-2	7570-7578	positive	_
43-3	7579-7590	correlation	_
43-4	7591-7600	threshold	_
43-5	7601-7603	of	_
43-6	7604-7605	r	_
43-7	7606-7607	=	_
43-8	7608-7611	0.2	_
43-9	7612-7613	(	_
43-10	7614-7624	sufficient	_
43-11	7625-7627	to	_
43-12	7628-7638	Bonferroni	_
43-13	7639-7646	correct	_
43-14	7647-7650	for	_
43-15	7651-7654	the	_
43-16	7655-7661	number	_
43-17	7662-7664	of	_
43-18	7665-7677	correlations	_
43-19	7678-7687	performed	_
43-20	7688-7690	in	_
43-21	7691-7694	the	_
43-22	7695-7706	subcortical	_
43-23	7707-7711	mask	_
43-24	7712-7713	,	_
43-25	7714-7715	p	_
43-26	7716-7717	<	_
43-27	7718-7719	1	_
43-28	7720-7721	×	_
43-29	7722-7726	10−4	_
43-30	7727-7728	)	_
43-31	7729-7732	was	_
43-32	7733-7737	used	_
43-33	7738-7740	to	_
43-34	7741-7748	compute	_
43-35	7749-7752	the	_
43-36	7753-7759	binary	_
43-37	7760-7772	connectivity	_
43-38	7773-7785	coefficients	_
43-39	7786-7787	,	_
43-40	7788-7791	aij	_
43-41	7792-7793	=	_
43-42	7794-7795	1	_
43-43	7796-7797	(	_
43-44	7798-7800	if	_
43-45	7801-7804	Cij	_
43-46	7805-7806	>	_
43-47	7807-7810	0.2	_
43-48	7811-7812	)	_
43-49	7813-7815	or	_
43-50	7816-7819	aij	_
43-51	7820-7821	=	_
43-52	7822-7823	0	_
43-53	7824-7825	(	_
43-54	7826-7828	if	_
43-55	7829-7832	Cij	_
43-56	7833-7834	≤	_
43-57	7835-7838	0.2	_
43-58	7839-7840	)	_
43-59	7841-7842	.	_

44-1	7843-7847	This	_
44-2	7848-7857	threshold	_
44-3	7858-7861	was	_
44-4	7862-7867	lower	_
44-5	7868-7872	than	_
44-6	7873-7881	previous	_
44-7	7882-7896	investigations	_
44-8	7897-7899	to	_
44-9	7900-7904	have	_
44-10	7905-7916	sensitivity	_
44-11	7917-7919	to	_
44-12	7920-7926	detect	_
44-13	7927-7934	effects	_
44-14	7935-7937	in	_
44-15	7938-7949	subcortical	_
44-16	7950-7957	regions	_
44-17	7958-7962	that	_
44-18	7963-7967	have	_
44-19	7968-7975	noisier	_
44-20	7976-7983	signals	_
44-21	7984-7988	than	_
44-22	7989-7992	the	_
44-23	7993-8002	neocortex	_
44-24	8003-8004	,	_
44-25	8005-8008	and	_
44-26	8009-8014	hence	_
44-27	8015-8019	have	_
44-28	8020-8026	weaker	_
44-29	8027-8035	observed	_
44-30	8036-8049	resting-state	_
44-31	8050-8062	correlations	_
44-32	8063-8064	.	_

45-1	8065-8068	The	_
45-2	8069-8074	local	_
45-3	8075-8078	FCD	_
45-4	8079-8080	(	_
45-5	8081-8083	or	_
45-6	8084-8085	‘	_
45-7	8086-8091	local	_
45-8	8092-8098	degree	_
45-9	8099-8100	’	_
45-10	8101-8102	)	_
45-11	8103-8106	for	_
45-12	8107-8112	voxel	_
45-13	8113-8114	i	_
45-14	8115-8118	was	_
45-15	8119-8127	computed	_
45-16	8128-8130	as	_
45-17	8131-8134	the	_
45-18	8135-8139	size	_
45-19	8140-8142	of	_
45-20	8143-8144	a	_
45-21	8145-8155	continuous	_
45-22	8156-8163	cluster	_
45-23	8164-8166	of	_
45-24	8167-8173	voxels	_
45-25	8174-8178	with	_
45-26	8179-8182	aij	_
45-27	8183-8184	=	_
45-28	8185-8186	1	_
45-29	8187-8188	,	_
45-30	8189-8193	that	_
45-31	8194-8197	are	_
45-32	8198-8207	connected	_
45-33	8208-8210	by	_
45-34	8211-8218	surface	_
45-35	8219-8220	.	_

46-1	8221-8222	A	_
46-2	8223-8224	‘	_
46-3	8225-8232	growing	_
46-4	8233-8234	’	_
46-5	8235-8244	algorithm	_
46-6	8245-8248	was	_
46-7	8249-8253	used	_
46-8	8254-8257	for	_
46-9	8258-8272	time-efficient	_
46-10	8273-8283	estimation	_
46-11	8284-8286	of	_
46-12	8287-8291	lFCD	_
46-13	8292-8293	.	_

47-1	8294-8304	Seed-based	_
47-2	8305-8315	functional	_
47-3	8316-8328	connectivity	_
47-4	8329-8337	analysis	_
47-5	8338-8340	To	_
47-6	8341-8348	examine	_
47-7	8349-8359	functional	_
47-8	8360-8372	connectivity	_
47-9	8373-8384	differences	_
47-10	8385-8389	with	_
47-11	8390-8395	other	_
47-12	8396-8403	regions	_
47-13	8404-8406	of	_
47-14	8407-8410	the	_
47-15	8411-8416	brain	_
47-16	8417-8418	,	_
47-17	8419-8421	we	_
47-18	8422-8430	computed	_
47-19	8431-8441	seed-based	_
47-20	8442-8454	connectivity	_
47-21	8455-8460	using	_
47-22	8461-8464	the	_
47-23	8465-8469	same	_
47-24	8470-8477	methods	_
47-25	8478-8480	as	_
47-26	8481-8484	our	_
47-27	8485-8493	previous	_
47-28	8494-8498	work	_
47-29	8499-8500	(	_
47-30	8501-8502	;	_
47-31	8503-8516	Supplementary	_
47-32	8517-8525	Material	_
47-33	8526-8527	)	_
47-34	8528-8529	.	_

48-1	8530-8541	Statistical	_
48-2	8542-8550	analysis	_
48-3	8551-8563	Second-level	_
48-4	8564-8575	statistical	_
48-5	8576-8584	analyses	_
48-6	8585-8589	were	_
48-7	8590-8599	conducted	_
48-8	8600-8602	in	_
48-9	8603-8608	SPM12	_
48-10	8609-8610	(	_
48-11	8611-8615	http	_
48-12	8616-8617	:	_
48-13	8618-8655	//www.fil.ion.ucl.ac.uk/spm/software/	_
48-14	8656-8657	)	_
48-15	8658-8661	for	_
48-16	8662-8669	imaging	_
48-17	8670-8674	data	_
48-18	8675-8678	and	_
48-19	8679-8681	in	_
48-20	8682-8690	Graphpad	_
48-21	8691-8696	Prism	_
48-22	8697-8701	7.02	_
48-23	8702-8703	(	_
48-24	8704-8707	San	_
48-25	8708-8713	Diego	_
48-26	8714-8715	,	_
48-27	8716-8718	CA	_
48-28	8719-8720	)	_
48-29	8721-8724	for	_
48-30	8725-8735	behavioral	_
48-31	8736-8740	data	_
48-32	8741-8742	.	_

49-1	8743-8748	First	_
49-2	8749-8750	,	_
49-3	8751-8753	to	_
49-4	8754-8761	examine	_
49-5	8762-8766	lFCD	_
49-6	8767-8773	across	_
49-7	8774-8777	the	_
49-8	8778-8784	larger	_
49-9	8785-8795	population	_
49-10	8796-8797	,	_
49-11	8798-8800	we	_
49-12	8801-8810	conducted	_
49-13	8811-8812	a	_
49-14	8813-8823	one-sample	_
49-15	8824-8830	T-test	_
49-16	8831-8833	of	_
49-17	8834-8838	lFCD	_
49-18	8839-8845	across	_
49-19	8846-8849	all	_
49-20	8850-8853	441	_
49-21	8854-8866	participants	_
49-22	8867-8868	.	_

50-1	8869-8873	Next	_
50-2	8874-8875	,	_
50-3	8876-8878	to	_
50-4	8879-8886	compare	_
50-5	8887-8889	CA	_
50-6	8890-8894	with	_
50-7	8895-8898	the	_
50-8	8899-8906	matched	_
50-9	8907-8914	control	_
50-10	8915-8920	group	_
50-11	8921-8922	,	_
50-12	8923-8925	we	_
50-13	8926-8935	conducted	_
50-14	8936-8937	a	_
50-15	8938-8948	two-sample	_
50-16	8949-8955	T-test	_
50-17	8956-8958	of	_
50-18	8959-8963	lFCD	_
50-19	8964-8971	between	_
50-20	8972-8978	groups	_
50-21	8979-8980	.	_

51-1	8981-8986	These	_
51-2	8987-8995	analyses	_
51-3	8996-9000	were	_
51-4	9001-9012	thresholded	_
51-5	9013-9015	at	_
51-6	9016-9017	p	_
51-7	9018-9019	<	_
51-8	9020-9024	.001	_
51-9	9025-9026	,	_
51-10	9027-9038	uncorrected	_
51-11	9039-9040	,	_
51-12	9041-9045	with	_
51-13	9046-9047	a	_
51-14	9048-9061	cluster-level	_
51-15	9062-9072	correction	_
51-16	9073-9075	of	_
51-17	9076-9077	p	_
51-18	9078-9079	<	_
51-19	9080-9083	.05	_
51-20	9084-9095	family-wise	_
51-21	9096-9101	error	_
51-22	9102-9103	(	_
51-23	9104-9107	FWE	_
51-24	9108-9109	)	_
51-25	9110-9119	corrected	_
51-26	9120-9121	,	_
51-27	9122-9125	and	_
51-28	9126-9127	a	_
51-29	9128-9135	minimum	_
51-30	9136-9143	cluster	_
51-31	9144-9148	size	_
51-32	9149-9151	of	_
51-33	9152-9153	k	_
51-34	9154-9155	=	_
51-35	9156-9159	100	_
51-36	9160-9166	voxels	_
51-37	9167-9168	.	_

52-1	9169-9171	To	_
52-2	9172-9179	control	_
52-3	9180-9193	cluster-level	_
52-4	9194-9198	type	_
52-5	9199-9200	I	_
52-6	9201-9206	error	_
52-7	9207-9212	rates	_
52-8	9213-9214	,	_
52-9	9215-9217	we	_
52-10	9218-9228	calculated	_
52-11	9229-9236	cluster	_
52-12	9237-9248	corrections	_
52-13	9249-9253	with	_
52-14	9254-9257	the	_
52-15	9258-9269	Statistical	_
52-16	9270-9283	nonparametric	_
52-17	9284-9291	mapping	_
52-18	9292-9299	toolbox	_
52-19	9300-9301	(	_
52-20	9302-9308	SnPM13	_
52-21	9309-9310	:	_
52-22	9311-9315	http	_
52-23	9316-9317	:	_
52-24	9318-9338	//warwick.ac.uk/snpm	_
52-25	9339-9340	;	_
52-26	9341-9345	5000	_
52-27	9346-9358	permutations	_
52-28	9359-9360	)	_
52-29	9361-9362	.	_

53-1	9363-9370	Because	_
53-2	9371-9375	lFCD	_
53-3	9376-9379	has	_
53-4	9380-9381	a	_
53-5	9382-9387	power	_
53-6	9388-9391	law	_
53-7	9392-9404	distribution	_
53-8	9405-9406	,	_
53-9	9407-9409	we	_
53-10	9410-9414	also	_
53-11	9415-9424	conducted	_
53-12	9425-9433	analyses	_
53-13	9434-9438	with	_
53-14	9439-9454	log-transformed	_
53-15	9455-9459	lFCD	_
53-16	9460-9466	values	_
53-17	9467-9468	;	_
53-18	9469-9473	this	_
53-19	9474-9477	did	_
53-20	9478-9481	not	_
53-21	9482-9487	alter	_
53-22	9488-9491	the	_
53-23	9492-9500	findings	_
53-24	9501-9502	,	_
53-25	9503-9506	and	_
53-26	9507-9509	so	_
53-27	9510-9512	we	_
53-28	9513-9519	report	_
53-29	9520-9525	these	_
53-30	9526-9530	data	_
53-31	9531-9533	in	_
53-32	9534-9547	Supplementary	_
53-33	9548-9556	material	_
53-34	9557-9558	.	_

54-1	9559-9561	We	_
54-2	9562-9566	also	_
54-3	9567-9576	conducted	_
54-4	9577-9587	two-sample	_
54-5	9588-9595	T-tests	_
54-6	9596-9598	on	_
54-7	9599-9602	the	_
54-8	9603-9609	volume	_
54-9	9610-9612	of	_
54-10	9613-9624	subcortical	_
54-11	9625-9631	nuclei	_
54-12	9632-9633	(	_
54-13	9634-9638	from	_
54-14	9639-9649	FreeSurfer	_
54-15	9650-9656	output	_
54-16	9657-9658	)	_
54-17	9659-9660	,	_
54-18	9661-9663	as	_
54-19	9664-9668	well	_
54-20	9669-9671	as	_
54-21	9672-9680	measures	_
54-22	9681-9683	of	_
54-23	9684-9693	cognition	_
54-24	9694-9697	and	_
54-25	9698-9706	negative	_
54-26	9707-9719	emotionality	_
54-27	9720-9721	.	_

55-1	9722-9724	To	_
55-2	9725-9732	examine	_
55-3	9733-9735	if	_
55-4	9736-9747	subcortical	_
55-5	9748-9752	lFCD	_
55-6	9753-9756	had	_
55-7	9757-9766	relevance	_
55-8	9767-9770	for	_
55-9	9771-9779	aberrant	_
55-10	9780-9789	cognition	_
55-11	9790-9796	and/or	_
55-12	9797-9805	negative	_
55-13	9806-9818	emotionality	_
55-14	9819-9821	in	_
55-15	9822-9824	CA	_
55-16	9825-9826	,	_
55-17	9827-9829	we	_
55-18	9830-9839	conducted	_
55-19	9840-9851	correlation	_
55-20	9852-9860	analysis	_
55-21	9861-9868	between	_
55-22	9869-9873	lFCD	_
55-23	9874-9876	in	_
55-24	9877-9884	regions	_
55-25	9885-9892	showing	_
55-26	9893-9904	significant	_
55-27	9905-9910	group	_
55-28	9911-9922	differences	_
55-29	9923-9926	and	_
55-30	9927-9929	in	_
55-31	9930-9940	behavioral	_
55-32	9941-9949	measures	_
55-33	9950-9957	showing	_
55-34	9958-9969	significant	_
55-35	9970-9975	group	_
55-36	9976-9987	differences	_
55-37	9988-9989	.	_

